Sarepta Therapeutics Announces Approval for SRP-1005 Clinical Trial in Huntington’s Disease
Sarepta Therapeutics, Inc. (NASDAQ: SRPT) has taken a significant step towards advancing treatments for Huntington’s Disease (HD) with the recent approval of its clinical trial application (CTA) for the investigational treatment SRP-1005. This milestone, announced on February 4, 2026, by Medsafe, New Zealand’s Medicines and Medical Devices Safety Authority, opens the door for the company to begin its first-in-human clinical trial, anticipated to commence in the second quarter of 2026.
1. Understanding SRP-1005 and the INSIGHTT Study
SRP-1005, previously known as ARO-HTT, is a small interfering RNA (siRNA) therapeutic specifically designed to target and treat Huntington’s Disease. The upcoming INSIGHTT Study represents a Phase 1, multi-center, dose escalation trial aimed at evaluating the safety and tolerability of SRP-1005 in approximately 24 participants.
Innovative Delivery Mechanism
One of the key innovations of SRP-1005 is its advanced delivery mechanism utilizing the transferrin receptor protein 1 (TfR1). This technology employs a monovalent fragment antigen-binding (fAb) approach to facilitate efficient delivery of the treatment to the central nervous system. By administering the drug subcutaneously, Sarepta aims to avoid saturating the transferrin receptor, thus ensuring robust and consistent penetration across the blood-brain barrier. Preclinical data has shown promising results, indicating significant protein knockdown in critical brain regions, including the putamen, caudate, temporal, and frontal cortexes.
2. The Impact of Huntington’s Disease
Huntington’s Disease is a rare, hereditary neurodegenerative disorder that leads to progressive deterioration of nerve cells in the brain, severely impacting cognition, movement, and behavior. In the United States alone, approximately 40,000 individuals are living with symptomatic HD, while an estimated 200,000 carry the gene mutation and are at risk of developing symptoms. The onset of HD typically occurs between ages 30 and 50, and there is currently no cure or approved treatments that modify the disease's progression.
3. Sarepta's Commitment to Genetic Medicine
Sarepta Therapeutics is recognized as a leader in precision genetic medicine, with a mission to develop treatments for rare diseases that can have devastating impacts on lives. The company’s siRNA platform focuses on chronic therapies for various neurodegenerative and pulmonary diseases, including:
- Facioscapulohumeral muscular dystrophy (FSHD)
- Myotonic dystrophy type 1 (DM1)
- Spinocerebellar ataxia type 2 (SCA2)
- Idiopathic pulmonary fibrosis (IPF)
- Huntington’s disease (HD)
In addition to SRP-1005, Sarepta is advancing preclinical programs targeting other forms of spinocerebellar ataxia and has an exclusive collaboration with Arrowhead Pharmaceuticals to explore therapies for skeletal muscle diseases.
4. Looking Ahead
The approval of the clinical trial for SRP-1005 represents a crucial development for both Sarepta Therapeutics and the Huntington’s Disease community. As the company prepares to initiate the INSIGHTT study, stakeholders are keenly watching how this innovative treatment could pave the way for advancements in addressing the underlying causes of HD.
With its robust portfolio and commitment to developing life-changing therapies, Sarepta continues to position itself at the forefront of genetic medicine, striving to bring hope and potential solutions to patients affected by rare and devastating diseases. As always, investors and interested parties are encouraged to follow Sarepta’s progress and updates, which can be found on their corporate website and social media channels.
